Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus gemcitabine for locally advanced pancreatic cancer
2016-001332-35Phase 3Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Amsterdam University Medical Center. Primary endpoint: Disease control. Started Jan 2017; status: active.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2016-001332-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001332-35.